Alvotech SA, a leading global biotech company, has expanded its partnership with Advanz Pharma, a UK-based pharmaceutical company, to commercialize three additional biosimilars in Europe. The agreement grants Advanz Pharma exclusive rights to market biosimilar candidates for Ilaris® (canakinumab) and Kesimpta® (ofatumumab), along with a third undisclosed biosimilar. This collaboration, which builds on previously partnered programs, underscores Advanz Pharma's commitment to enhancing access to rare disease and specialty medicines. The partnership involves development and commercial milestones worth up to US$180 million and includes a revenue-sharing model. Alvotech will handle development and supply, while Advanz Pharma will focus on registration and commercialization in Europe.